$53.56
1.14% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US00973Y1082
Symbol
AKRO

Akero Therapeutics Inc Stock price

$53.56
+12.03 28.97% 1M
+24.53 84.50% 6M
+25.74 92.52% YTD
+29.27 120.50% 1Y
+29.28 120.59% 5Y
+37.56 234.75% 10Y
+37.56 234.75% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.61 1.14%
ISIN
US00973Y1082
Symbol
AKRO

Key metrics

Market capitalization $4.27b
Enterprise Value $3.62b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.94
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-306.61m
Free Cash Flow (TTM) Free Cash Flow $-262.77m
Cash position $686.29m
EPS (TTM) EPS $-3.42
P/E forward negative
Short interest 8.92%
Show more

Is Akero Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Akero Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Akero Therapeutics Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Akero Therapeutics Inc forecast:

Buy
100%

Financial data from Akero Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
18% 18%
-
- Research and Development Expense 266 266
56% 56%
-
-307 -307
50% 50%
-
- Depreciation and Amortization 0.02 0.02
0% 0%
-
EBIT (Operating Income) EBIT -307 -307
50% 50%
-
Net Profit -269 -269
51% 51%
-

In millions USD.

Don't miss a Thing! We will send you all news about Akero Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akero Therapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. E.T.
Neutral
GlobeNewsWire
16 days ago
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m.
Neutral
Seeking Alpha
23 days ago
Akero Therapeutics' efruxifermin shows strong potential in MASH, especially compensated cirrhosis, with positive 96-week phase 2b data published in NEJM. The SYNCHRONY phase 3 program targets a broad MASH population, positioning Akero for significant market opportunity and acquisition interest. GlaxoSmithKline's $1.2B acquisition of FGF21 asset validates the value of Akero's approach and increa...
More Akero Therapeutics Inc News

Company Profile

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Head office United States
CEO Andrew Cheng
Employees 63
Founded 2017
Website akerotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today